Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study.
Journal
The Lancet. Respiratory medicine
ISSN: 2213-2619
Titre abrégé: Lancet Respir Med
Pays: England
ID NLM: 101605555
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
05
07
2019
revised:
09
09
2019
accepted:
11
09
2019
pubmed:
18
2
2020
medline:
21
8
2020
entrez:
17
2
2020
Statut:
ppublish
Résumé
The observation that patients with idiopathic pulmonary fibrosis (IPF) can have higher than normal expiratory flow rates at low lung volumes led to the conclusion that the airways are spared in IPF. This study aimed to re-examine the hypothesis that airways are spared in IPF using a multiresolution imaging protocol that combines multidetector CT (MDCT), with micro-CT and histology. This was a retrospective cohort study comparing explanted lungs from patients with severe IPF treated by lung transplantation with a cohort of unused donor (control) lungs. The donor control lungs had no known lung disease, comorbidities, or structural lung injury, and were deemed appropriate for transplantation on review of the clinical files. The diagnosis of IPF in the lungs from patients was established by a multidisciplinary consensus committee according to existing guidelines, and was confirmed by video-assisted thoracic surgical biopsy or by pathological examination of the contralateral lung. The control and IPF groups were matched for age, sex, height, and bodyweight. Samples of lung tissue were compared using the multiresolution imaging approach: a cascade of clinical MDCT, micro-CT, and histological imaging. We did two experiments: in experiment 1, all the lungs were randomly sampled; in experiment 2, samples were selected from regions of minimal and established fibrosis. The patients and donors were recruited from the Katholieke Universiteit Leuven (Leuven, Belgium) and the University of Pennsylvania Hospital (Philadelphia, PA, USA). The study took place at the Katholieke Universiteit Leuven, and the University of British Columbia (Vancouver, BC, Canada). Between Oct 5, 2009, and July 22, 2016, explanted lungs from patients with severe IPF (n=11), were compared with a cohort of unused donor (control) lungs (n=10), providing 240 samples of lung tissue for comparison using the multiresolution imaging approach. The MDCT specimen scans show that the number of visible airways located between the ninth generation (control 69 [SD 22] versus patients with IPF 105 [33], p=0·0023) and 14th generation (control 9 [6] versus patients with IPF 49 [28], p<0·0001) of airway branching are increased in patients with IPF, which we show by micro-CT is due to thickening of their walls and distortion of their lumens. The micro-CT analysis showed that compared with healthy (control) lung anatomy (mean 5·6 terminal bronchioles per mL [SD 1·6]), minimal fibrosis in IPF tissue was associated with a 57% loss of the terminal bronchioles (mean 2·4 terminal bronchioles per mL [SD 1·0]; p<0·0001), the appearance of fibroblastic foci, and infiltration of the tissue by inflammatory immune cells capable of forming lymphoid follicles. Established fibrosis in IPF tissue had a similar reduction (66%) in the number of terminal bronchioles (mean 1·9 terminal bronchioles per mL [SD 1·4]; p<0·0001) and was dominated by increased airspace size, Ashcroft fibrosis score, and volume fractions of tissue and collagen. Small airways disease is a feature of IPF, with significant loss of terminal bronchioles occuring within regions of minimal fibrosis. On the basis of these findings, we postulate that the small airways could become a potential therapeutic target in IPF. Katholieke Universiteit Leuven, US National Institutes of Health, BC Lung Association, and Genentech.
Sections du résumé
BACKGROUND
The observation that patients with idiopathic pulmonary fibrosis (IPF) can have higher than normal expiratory flow rates at low lung volumes led to the conclusion that the airways are spared in IPF. This study aimed to re-examine the hypothesis that airways are spared in IPF using a multiresolution imaging protocol that combines multidetector CT (MDCT), with micro-CT and histology.
METHODS
This was a retrospective cohort study comparing explanted lungs from patients with severe IPF treated by lung transplantation with a cohort of unused donor (control) lungs. The donor control lungs had no known lung disease, comorbidities, or structural lung injury, and were deemed appropriate for transplantation on review of the clinical files. The diagnosis of IPF in the lungs from patients was established by a multidisciplinary consensus committee according to existing guidelines, and was confirmed by video-assisted thoracic surgical biopsy or by pathological examination of the contralateral lung. The control and IPF groups were matched for age, sex, height, and bodyweight. Samples of lung tissue were compared using the multiresolution imaging approach: a cascade of clinical MDCT, micro-CT, and histological imaging. We did two experiments: in experiment 1, all the lungs were randomly sampled; in experiment 2, samples were selected from regions of minimal and established fibrosis. The patients and donors were recruited from the Katholieke Universiteit Leuven (Leuven, Belgium) and the University of Pennsylvania Hospital (Philadelphia, PA, USA). The study took place at the Katholieke Universiteit Leuven, and the University of British Columbia (Vancouver, BC, Canada).
FINDINGS
Between Oct 5, 2009, and July 22, 2016, explanted lungs from patients with severe IPF (n=11), were compared with a cohort of unused donor (control) lungs (n=10), providing 240 samples of lung tissue for comparison using the multiresolution imaging approach. The MDCT specimen scans show that the number of visible airways located between the ninth generation (control 69 [SD 22] versus patients with IPF 105 [33], p=0·0023) and 14th generation (control 9 [6] versus patients with IPF 49 [28], p<0·0001) of airway branching are increased in patients with IPF, which we show by micro-CT is due to thickening of their walls and distortion of their lumens. The micro-CT analysis showed that compared with healthy (control) lung anatomy (mean 5·6 terminal bronchioles per mL [SD 1·6]), minimal fibrosis in IPF tissue was associated with a 57% loss of the terminal bronchioles (mean 2·4 terminal bronchioles per mL [SD 1·0]; p<0·0001), the appearance of fibroblastic foci, and infiltration of the tissue by inflammatory immune cells capable of forming lymphoid follicles. Established fibrosis in IPF tissue had a similar reduction (66%) in the number of terminal bronchioles (mean 1·9 terminal bronchioles per mL [SD 1·4]; p<0·0001) and was dominated by increased airspace size, Ashcroft fibrosis score, and volume fractions of tissue and collagen.
INTERPRETATION
Small airways disease is a feature of IPF, with significant loss of terminal bronchioles occuring within regions of minimal fibrosis. On the basis of these findings, we postulate that the small airways could become a potential therapeutic target in IPF.
FUNDING
Katholieke Universiteit Leuven, US National Institutes of Health, BC Lung Association, and Genentech.
Identifiants
pubmed: 32061334
pii: S2213-2600(19)30356-X
doi: 10.1016/S2213-2600(19)30356-X
pmc: PMC7292784
mid: NIHMS1563047
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
573-584Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL141852
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL127349
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL139690
Pays : United States
Organisme : NHLBI NIH HHS
ID : R44 HL118837
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL122626
Pays : United States
Organisme : NHGRI NIH HHS
ID : U54 HG008540
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL145567
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Am J Respir Crit Care Med. 2017 Mar 1;195(5):630-638
pubmed: 27611890
JAMA. 2016 Feb 16;315(7):672-81
pubmed: 26881370
Am J Respir Crit Care Med. 2014 Feb 1;189(3):292-300
pubmed: 24354907
J Appl Physiol (1985). 2013 Mar 15;114(6):716-24
pubmed: 23264542
N Engl J Med. 2011 Oct 27;365(17):1567-75
pubmed: 22029978
J Appl Physiol (1985). 2017 Jan 1;122(1):161-169
pubmed: 27856720
N Engl J Med. 2004 Jun 24;350(26):2645-53
pubmed: 15215480
Eur Respir J. 2015 Nov;46(5):1430-9
pubmed: 26113688
Am J Respir Crit Care Med. 1997 May;155(5):1649-56
pubmed: 9154871
Lancet. 2011 May 21;377(9779):1760-9
pubmed: 21571362
Nat Med. 2012 Nov;18(11):1711-5
pubmed: 23042237
Chest. 2018 Jun;153(6):1416-1423
pubmed: 29608882
Hum Pathol. 2008 Nov;39(11):1562-81
pubmed: 19653362
Eur Respir J. 2018 Feb 14;51(2):
pubmed: 29444912
JCI Insight. 2016 Apr 21;1(5):
pubmed: 27275013
Am J Respir Crit Care Med. 2002 Jul 15;166(2):173-7
pubmed: 12119229
J Clin Pathol. 1988 Apr;41(4):467-70
pubmed: 3366935
Am J Respir Crit Care Med. 2016 Mar 1;193(5):516-26
pubmed: 26551917
Thorax. 1952 Sep;7(3):213-39
pubmed: 12984409
Arch Pathol. 1960 Jul;70:79-93
pubmed: 13793353
J Clin Invest. 1977 Sep;60(3):595-610
pubmed: 893665
Histopathology. 2008 Dec;53(6):707-14
pubmed: 19102010
Eur Respir J. 2005 Oct;26(4):586-93
pubmed: 16204587
Lancet Respir Med. 2018 Aug;6(8):591-602
pubmed: 30072106
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Physiol Rev. 2016 Oct;96(4):1567-91
pubmed: 27630174
Eur Respir J. 2015 Oct;46(4):976-87
pubmed: 26160873
N Engl J Med. 1970 Jun 4;282(23):1318-9
pubmed: 5442364
Am Rev Respir Dis. 1977 Oct;116(4):637-47
pubmed: 921050
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Lancet Respir Med. 2018 Feb;6(2):138-153
pubmed: 29154106
Am J Respir Crit Care Med. 2006 Sep 15;174(6):654-8
pubmed: 16799077
Hum Pathol. 2010 Mar;41(3):316-25
pubmed: 20004953
Am J Respir Crit Care Med. 2019 Sep 1;200(5):575-581
pubmed: 30794432